The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Entest Biomedical are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Entest Biomedical has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Entest Biomedical is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Begin Period Cash Flow
267.00
Total Cashflows From Investing Activities
1937.00
Free Cash Flow
-3959.00
Entest
Entest Biomedical Relative Risk vs. Return Landscape
If you would invest 0.02 in Entest Biomedical on December 1, 2025 and sell it today you would earn a total of 0.00 from holding Entest Biomedical or generate 0.0% return on investment over 90 days. Entest Biomedical is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Entest, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Entest Biomedical Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Entest Biomedical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Entest Biomedical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Entest Biomedical generated a negative expected return over the last 90 days
Entest Biomedical has some characteristics of a very speculative penny stock
Entest Biomedical has high likelihood to experience some financial distress in the next 2 years
Entest Biomedical currently holds 38.29 K in liabilities with Debt to Equity (D/E) ratio of 27.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Entest Biomedical has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Entest Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Entest Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entest Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entest to invest in growth at high rates of return. When we think about Entest Biomedical's use of debt, we should always consider it together with cash and equity.
Entest Biomedical currently holds about 423.97 K in cash with (3.96 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Entest Biomedical Fundamentals Growth
Entest Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Entest Biomedical, and Entest Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entest Pink Sheet performance.
By evaluating Entest Biomedical's fundamental ratios, stakeholders can gain valuable insights into Entest Biomedical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Entest Biomedical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Entest Biomedical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
It intends to seek business opportunities to review and analyze for purposes of effecting a merger, acquisition, or other business combination with an operating company business. Entest Group, Inc. was founded in 2008 and is based in Shenzhen, China. Entest is traded on OTC Exchange in the United States.
Things to note about Entest Biomedical performance evaluation
Checking the ongoing alerts about Entest Biomedical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Entest Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Entest Biomedical generated a negative expected return over the last 90 days
Entest Biomedical has some characteristics of a very speculative penny stock
Entest Biomedical has high likelihood to experience some financial distress in the next 2 years
Entest Biomedical currently holds 38.29 K in liabilities with Debt to Equity (D/E) ratio of 27.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Entest Biomedical has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Entest Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Entest Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entest Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entest to invest in growth at high rates of return. When we think about Entest Biomedical's use of debt, we should always consider it together with cash and equity.
Entest Biomedical currently holds about 423.97 K in cash with (3.96 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating Entest Biomedical's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Entest Biomedical's pink sheet performance include:
Analyzing Entest Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entest Biomedical's stock is overvalued or undervalued compared to its peers.
Examining Entest Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Entest Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entest Biomedical's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Entest Biomedical's pink sheet. These opinions can provide insight into Entest Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Entest Biomedical's pink sheet performance is not an exact science, and many factors can impact Entest Biomedical's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Complementary Tools for Entest Pink Sheet analysis
When running Entest Biomedical's price analysis, check to measure Entest Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entest Biomedical is operating at the current time. Most of Entest Biomedical's value examination focuses on studying past and present price action to predict the probability of Entest Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entest Biomedical's price. Additionally, you may evaluate how the addition of Entest Biomedical to your portfolios can decrease your overall portfolio volatility.
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance